Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 4,804,428 |
|
|||||
| News | - | ||||||
| Day High | 17.00 | Low High |
|||||
| Day Low | 15.96 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| TG Therapeutics Inc | TGTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.41 | -2.50% | 16.01 | 00:00:02 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.75 | 15.96 | 17.00 | 16.19 | 16.42 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 42,185 | 4,804,428 | $ 16.38 | $ 78,698,726 | - | 6.46 - 35.67 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:49 | formt | 125 | $ 16.01 | USD |
TG Therapeutics (TGTX) Options Flow Summary
TG Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.5B | 154.42M | - | 233.66M | 12.67M | 0.08 | 197.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
TG Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TGTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 13.94 | 18.00 | 12.93 | 15.32 | 7,608,904 | 2.07 | 14.85% |
| 1 Month | 14.43 | 18.00 | 12.93 | 14.75 | 3,979,016 | 1.58 | 10.95% |
| 3 Months | 14.83 | 19.0175 | 12.84 | 15.31 | 3,754,858 | 1.18 | 7.96% |
| 6 Months | 10.86 | 22.67 | 9.81 | 15.37 | 4,618,488 | 5.15 | 47.42% |
| 1 Year | 31.45 | 35.67 | 6.46 | 15.48 | 4,797,918 | -15.44 | -49.09% |
| 3 Years | 45.25 | 45.50 | 3.48 | 14.56 | 3,506,351 | -29.24 | -64.62% |
| 5 Years | 7.89 | 56.74 | 3.48 | 16.34 | 2,795,000 | 8.12 | 102.92% |
TG Therapeutics Description
| TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. |
